Peregrine Pharmaceuticals
PPHM today announced results from its 70 patient
open-label, randomized Phase II clinical trial of bavituximab used in
combination with gemcitabine in patients with previously untreated,
advanced Stage IV pancreatic cancer. The trial included the
enrollment of patients with advanced metastatic disease including
significant liver involvement and poor performance status associated
with rapid disease progression. Results showed that the combination
of bavituximab and gemcitabine resulted in more than a doubling of
overall response rates (ORR) and an improvement in overall survival
(OS) when compared with gemcitabine alone (control arm). In the trial, patients treated with a combination of bavituximab and
gemcitabine had a 28% tumor response rate as compared to 13% in the
control arm. Median OS, the primary endpoint of the trial, was 5.6
months for the bavituximab plus gemcitabine arm and 5.2 months for
the control
arm (hazard ratio = 0.75).
The pancreatic cancer trial is a randomized, open-label Phase II
trial evaluating bavituximab with gemcitabine versus gemcitabine
alone in up to 70 patients with previously untreated stage IV pancreatic cancer. The trial allowed the enrollment of patients 18
and older without any age limit, distant organ involvement and ECOG
performance status of 0-2. In this trial, bavituximab was generally
safe and well tolerated in combination with gemcitabine with similar
adverse events occurring in both arms.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in